UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

Gut, 2007-05, Vol.56 (5), p.699-705

2007

Volltextzugriff (PDF)

Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

Gut, 2007-05, Vol.56 (5), p.699-705

2007

Volltextzugriff (PDF)

Antiviral properties from plants of the Mediterranean flora

Natural product research, 2015-11, Vol.29 (22), p.2065-2070

2015

Volltextzugriff (PDF)

Delta hepatitis: an update

Journal of hepatology, 2003, Vol.39, p.212-219

Farci, Patrizia

2003

Volltextzugriff (PDF)

Diminished Replication and Viral Compartmentalization of Hepatitis C Virus in Hepatocellular Carcinoma Tissue

Journal of hepatology, 2016, Vol.64 (2), p.S421-S421

2016

Volltextzugriff (PDF)

P1191 HETEROGENEOUS EVOLUTIONARY DYNAMICS OF CHRONIC HEPATITIS-C INFECTION PREDICT LONG-TERM PERSISTENCE OF VIRUS THROUGH TREATMENT

Journal of hepatology, 2014-04, Vol.60 (1), p.S483-S483

2014

Volltextzugriff (PDF)

Treatment of chronic hepatitis D

Journal of viral hepatitis, 2007-11, Vol.14 (s1), p.58-63

2007

Volltextzugriff (PDF)

Prevention of Hepatitis C Virus Infection in Chimpanzees After Antibody-Mediated in vitro Neutralization

Proceedings of the National Academy of Sciences - PNAS, 1994-08, Vol.91 (16), p.7792-7796

1994

Volltextzugriff (PDF)

524 RESPONSE-GUIDED PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEK 12 AND WEEK 24 OR 48 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE, GENOTYPE D PATIENTS

Journal of hepatology, 2012-04, Vol.56, p.S207-S208

2012

Volltextzugriff (PDF)

Identification of microRNAs specifically expressed in hepatitis C virus‐associated hepatocellular carcinoma

International journal of cancer, 2013-08, Vol.133 (4), p.816-824

2013

Volltextzugriff (PDF)

730 PEGBELIVER STUDY: HBSAG DECLINE AT WEEK 24 OF EXTENDED PEGINTERFERON ALFA-2A (PEG-IFNα-2A) THERAPY IS SIGNIFICANTLY ASSOCIATED WITH POST-TREATMENT RESPONSE IN HBEAG-NEGATIVE GENOTYPE D PATIENTS

Journal of hepatology, 2011-03, Vol.54, p.S293-S293

2011

Volltextzugriff (PDF)

Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1

Journal of Virology, 1995-06, Vol.69 (6), p.3712-3720

1995

Volltextzugriff (PDF)

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

Science (American Association for the Advancement of Science), 1992-10, Vol.258 (5079), p.135-140

1992

Volltextzugriff (PDF)

Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

The New England journal of medicine, 2004-09, Vol.351 (12), p.1206-1217

2004

Volltextzugriff (PDF)

98 EXTENDED (2 YEARS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IMPROVES SUSTAINED RESPONSE RATES IN GENOTYPE D PATIENTS WITH HBEAG NEGATIVE CHRONIC HEPATITIS B

Journal of hepatology, 2010, Vol.52, p.S45-S45

2010

Volltextzugriff (PDF)

F-51 Virological response and HBV-DNA reduction during therapy with peginterferon alpha-2a (PEG-IFNα-2a) in patients affected by HBeAg-negative chronic hepatitis B

Digestive and liver disease, 2012-02, Vol.44, p.S48-S48

2012

Volltextzugriff (PDF)

683 ON-TREATMENT HBSAG DECLINE IN HBEAG-NEGATIVE PATIENTS AS A PREDICTOR OF RESPONSE TO PEGINTERFERON ALFA-2A (40KD) THERAPY 3 YEARS POST-TREATMENT: POTENTIAL FOR RESPONSE-GUIDED THERAPY

Journal of hepatology, 2008, Vol.48, p.S254-S254

2008

Volltextzugriff (PDF)

924 INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH PEGINTERFERON ALFA-2A ± LAMIVUDINE: RESULTS OF 5-YEAR POST-TREATMENT FOLLOW UP

Journal of hepatology, 2009, Vol.50, p.S336-S336

2009

Volltextzugriff (PDF)

The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase

Journal of viral hepatitis, 2006-06, Vol.13 (6), p.377-386

2006

Volltextzugriff (PDF)

Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children

The Lancet (British edition), 1994-02, Vol.343 (8894), p.388-390

1994

Volltextzugriff (PDF)

The use of molecular assays in the management of viral hepatitis

Digestive and liver disease, 2008-06, Vol.40 (6), p.395-404

2008

Volltextzugriff (PDF)

F-7 Insulin resistance does not affect sustained virologic response in patients with chronic hepatitis C without cirrhosis treated with peg-interferon alfa 2a and ribavirin

Digestive and liver disease, 2011, Vol.43, p.S94-S94

2011

Volltextzugriff (PDF)

103 VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A (40KD) WITH OR WITHOUT LAMIVUDINE: RESULTS OF 4-YEAR FOLLOW-UP

Journal of hepatology, 2008, Vol.48, p.S46-S46

2008

Volltextzugriff (PDF)

Early Changes in Hepatitis C Viral Quasispecies during Interferon Therapy Predict the Therapeutic Outcome

Proceedings of the National Academy of Sciences - PNAS, 2002-03, Vol.99 (5), p.3081-3086

2002

Volltextzugriff (PDF)

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

Gastroenterology (New York, N.Y. 1943), 2004-12, Vol.127 (6), p.1724-1732

2004

Volltextzugriff (PDF)

1 – 25 von 191

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(179)
Mit Volltextzugriff
(150)

Publikationsform

Artikel
(190)
Tagungsberichte
(1)

Sprache

Englisch
(182)
Italienisch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

Antiviral properties from plants of the Mediterranean flora

Delta hepatitis: an update

Diminished Replication and Viral Compartmentalization of Hepatitis C Virus in Hepatocellular Carcinoma Tissue

P1191 HETEROGENEOUS EVOLUTIONARY DYNAMICS OF CHRONIC HEPATITIS-C INFECTION PREDICT LONG-TERM PERSISTENCE OF VIRUS THROUGH TREATMENT

Treatment of chronic hepatitis D

Prevention of Hepatitis C Virus Infection in Chimpanzees After Antibody-Mediated in vitro Neutralization

524 RESPONSE-GUIDED PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEK 12 AND WEEK 24 OR 48 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE, GENOTYPE D PATIENTS

Identification of microRNAs specifically expressed in hepatitis C virus‐associated hepatocellular carcinoma

730 PEGBELIVER STUDY: HBSAG DECLINE AT WEEK 24 OF EXTENDED PEGINTERFERON ALFA-2A (PEG-IFNα-2A) THERAPY IS SIGNIFICANTLY ASSOCIATED WITH POST-TREATMENT RESPONSE IN HBEAG-NEGATIVE GENOTYPE D PATIENTS

Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

98 EXTENDED (2 YEARS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IMPROVES SUSTAINED RESPONSE RATES IN GENOTYPE D PATIENTS WITH HBEAG NEGATIVE CHRONIC HEPATITIS B

F-51 Virological response and HBV-DNA reduction during therapy with peginterferon alpha-2a (PEG-IFNα-2a) in patients affected by HBeAg-negative chronic hepatitis B

683 ON-TREATMENT HBSAG DECLINE IN HBEAG-NEGATIVE PATIENTS AS A PREDICTOR OF RESPONSE TO PEGINTERFERON ALFA-2A (40KD) THERAPY 3 YEARS POST-TREATMENT: POTENTIAL FOR RESPONSE-GUIDED THERAPY

924 INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH PEGINTERFERON ALFA-2A ± LAMIVUDINE: RESULTS OF 5-YEAR POST-TREATMENT FOLLOW UP

The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase

Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children

The use of molecular assays in the management of viral hepatitis

F-7 Insulin resistance does not affect sustained virologic response in patients with chronic hepatitis C without cirrhosis treated with peg-interferon alfa 2a and ribavirin

103 VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A (40KD) WITH OR WITHOUT LAMIVUDINE: RESULTS OF 4-YEAR FOLLOW-UP

Early Changes in Hepatitis C Viral Quasispecies during Interferon Therapy Predict the Therapeutic Outcome

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

Suchergebnisse filtern